Amicus Therapeutics, Inc. (FOLD)
Whether directors and officers of Amicus Therapeutics, Inc. (FOLD) breached their fiduciary duties to the company and its shareholders.
Investigation
03/02/2022
Initial Lawsuit
03/16/2022
Lawsuit Progression
06/07/2022
Whether Grab issued misleading statements related to the release of its Q4 $1.1 billion loss and heavy investment in driver and consumer incentives to “preemptively recalibrate driver supply.”
This post is open for investors to gather facts, and findings and track their exposure to related lawsuits. We invite investors and shareholders to contribute to this investigation for their own benefit, add events to the factual timeline below and vote on events’ pertinence.
A lawsuit was subsequently filed. We will update this post as it unfolds.
03/03/2022
Grab releases its financial results for the fourth quarter and full year ended December 31, 2021, including a $1.1 billion and revenue of $122 million, a 44% decline year over year “as Grab preemptively invested to grow driver supply to support strong recovery in mobility demand.”
Peter Oey, its chief financial officer affirmed that the company “plan to be judicious and disciplined in allocating capital” as they “double down on the long-term growth opportunities of [their] on-demand, advertising and financial services businesses.”
Stock Impact
Close | Previous close | Price variation | Percentage variation |
---|---|---|---|
$3.28 | $5.23 | $-1.95 | -37.28% |
An investor filed a securities class action lawsuit on behalf of persons and entities that purchased or otherwise acquired Grab Holdings Limited securities between November 12, 2021 and March 3, 2022, inclusive.
According to the complaint, defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the company’s business, operations, and prospects. Specifically, defendants allegedly failed to disclose to investors:
(1) that Grab’s driver supply declined during the third quarter;
(2) that, as a result, Grab continued to invest heavily in driver and consumer incentives to “preemptively recalibrate driver supply”;
(3) that, as a result, the company’s financial results would be adversely impacted, including, among other things, a significant decline in revenue; and
(4) that, as a result of the foregoing, defendants’ positive statements about the company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
06/07/2022
The court issued an order appointing the lead plaintiff and lead counsel.
Whether directors and officers of Amicus Therapeutics, Inc. (FOLD) breached their fiduciary duties to the company and its shareholders.
Whether directors and officers of Builders FirstSource, Inc. (BLDR) breached their fiduciary duties to the company and its shareholders.
Whether directors and officers of Kewaunee Scientific Corporation (KEQU) breached their fiduciary duties to the company and its shareholders.
Whether directors and officers of LegalZoom.com, Inc. (LZ) breached their fiduciary duties to the company and its shareholders.
Whether directors and officers of Payoneer Global Inc. (PAYO) breached their fiduciary duties to the company and its shareholders.
Confidential investigation: officers & directors’ potential breach of fiduciary duties to investors.